These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11404515)

  • 1. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical resource utilization and cost of HIV-related care in the highly active antiretroviral therapy era at a University Clinic in Sweden.
    Ghatnekar O; Hjortsberg C; Gisslén M; Lindbäck S; Löthgren M
    Pharmacoeconomics; 2010; 28 Suppl 1():49-57. PubMed ID: 21182343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs of care for HIV infection in a managed care population from 1995 to 1997.
    Lapins DL; Urdaneta ME; Barrett J; Hamel EC; Duong PT; Markson LE
    Am J Manag Care; 2000 Sep; 6(9):973-81. PubMed ID: 11184068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration hospital.
    Keiser P; Kvanli MB; Turner D; Reisch J; Smith JW; Nassar N; Gregg C; Skiest D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1999 Jan; 20(1):28-33. PubMed ID: 9928726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
    Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
    AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002.
    Fleishman JA; Gebo KA; Reilly ED; Conviser R; Christopher Mathews W; Todd Korthuis P; Hellinger J; Rutstein R; Keiser P; Rubin H; Moore RD;
    Med Care; 2005 Sep; 43(9 Suppl):III40-52. PubMed ID: 16116308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications of health resource-use in Italy after the introduction of highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV) infection. Pharmaco-economic implications in a population-based setting.
    Torti C; Casari S; Palvarini L; Quiros-Roldan E; Moretti F; Leone L; Patroni A; Castelli F; Ripamonti D; Tramarin A; Carosi G
    Health Policy; 2003 Sep; 65(3):261-7. PubMed ID: 12941493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of HAART on health status and hospital costs of severe HIV-infected patients: a modeling approach.
    Le Pen C; Rozenbaum W; Downs A; Maurel F; Lilliu H; Brun C
    HIV Clin Trials; 2001; 2(2):136-45. PubMed ID: 11590522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of highly active antiretroviral therapy in South Africa.
    Badri M; Maartens G; Mandalia S; Bekker LG; Penrod JR; Platt RW; Wood R; Beck EJ
    PLoS Med; 2006 Jan; 3(1):e4. PubMed ID: 16318413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
    Simpson KN; Luo MP; Chumney EC; King MS; Brun S
    Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do reduced inpatient costs associated with highly active antiretroviral therapy (HAART) balance the overall cost for HIV treatment?
    Farnham PG
    Appl Health Econ Health Policy; 2010; 8(2):75-88. PubMed ID: 20175587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of management strategies and clinical status on costs of care for advanced HIV.
    Barnett PG; Chow A; Joyce VR; Bayoumi AM; Griffin SC; Sun H; Holodniy M; Brown ST; Cameron W; Sculpher M; Youle M; Anis AH; Owens DK
    Am J Manag Care; 2014 May; 20(5):e129-37. PubMed ID: 25326927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
    Sánchez-de la Rosa R; Herrera L; Moreno S
    Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year effectiveness of highly active antiretroviral treatment in the Luxembourg HIV cohort.
    Servais J; Schmit JC; Arendt V; Lambert C; Staub T; Robert I; Fontaine E; Plesséria JM; Burgy C; Kirpach P; Schneider F; Hemmer R
    HIV Clin Trials; 2000; 1(2):17-24. PubMed ID: 11590494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.
    McCabe CJ; Goldie SJ; Fisman DN
    PLoS One; 2010 Apr; 5(4):e10154. PubMed ID: 20405011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.